Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

Summary

RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.

Timeline

Start

2002-08

Primary completion

—

Completion

—

Drugs

Indications